Journal
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
Volume 35, Issue 3, Pages 818-825Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neubiorev.2010.10.002
Keywords
Major depressive disorder; Cortical inhibition; GABA; Transcranial magnetic stimulation; Interneuron
Categories
Funding
- National Institutes of Health (NIH) [UL1 RR024982]
- National Alliance for Research on Schizophrenia and Depression (NARSAD)
- Canadian Institutes of Health Research (CIHR)
- Ontario Mental Health Foundation
- NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024982] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Converging evidence suggests that deficits in gamma-aminobutyric acid (GABA) functioning are implicated in the pathophysiology of major depressive disorder (MDD). This is highlighted by research investigating cortical inhibition (Cl), a process whereby GABAergic interneurons selectively attenuate pyramidal neurons. Transcranial magnetic stimulation (TMS) paradigms evaluate this marker of neuronal inhibitory activity in the cortex. This review will examine the neuroanatomic and neurophysiological evidence from neuroimaging, molecular, treatment, and TMS studies linking dysfunctional GABAergic neurotransmission to MDD. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
